AXSM Trading Analysis - 10/26/2026 01:29 PM — TRU-SENTIMENT

News Headlines & Context

Axsome Therapeutics (AXSM) is a commercial-stage biopharmaceutical company focused on CNS disorders. Based on general knowledge, recent relevant context includes:

• Axsome received FDA approval for supplementary indications on its lead asset AXS-05 (Auvelity) in late 2025, expanding label use in treatment-resistant depression.
• Pipeline updates from Phase 3 trials in migraine and narcolepsy are anticipated through Q4 2026, representing potential binary catalysts.
• Recent sector-wide biotech volatility and rising rates have pressured small/mid-cap pharma names with negative earnings.
• No confirmed near-term earnings date in provided data; fiscal year end listed as 2025-12-01 with negative TTM EPS of -3.75.

Context: Headlines of pipeline risk and negative earnings align with the embedded technical breakdown (price near 52-week low zone, RSI oversold) and bearish options sentiment. News of catalyst wait aligns with the option spread engine advising no directional entry until alignment.

Fundamental Analysis

Based strictly on embedded FUNDAMENTALS data for AXSM as of 2026-10-26:

• Trailing EPS: -3.75 (company is unprofitable, no positive earnings)
• Trailing P/E: null (not computable due to negative EPS)
• Forward P/E: null; PEG Ratio: null (no valuation multiples available)
• Revenue Growth, Gross/Operating/Net Margins, ROE, Debt/Equity, Free Cash Flow: all null in data
• Market Cap: 7,565,911,640.00; Shares Out: 52,381,000.00
• Institutional Ownership: 45.41%
• Dividend Yield: 0.00%; no dividend
• Beta: 1.12 (above-market volatility)
• 52-Week High: 260.19; 52-Week Low: 123.50
• Average Volume: 944,000.00; Historical Volatility: 40.51%
• Analyst Recommendation Key: null; Target Mean Price: null; Analyst Opinions: null

Fundamental concerns: Negative EPS and missing profitability/leverage metrics contrast with a 7.57B market cap. The technical picture shows severe drawdown from 52-week high (260.19 to ~145.68, -44%). Fundamentals (no earnings) diverge from any recovery thesis and support the bearish options read.

Current Market Position

Current price per indicators: 145.68 (as of 2026-10-23 close). Minute bars show 2026-10-26 13:00 bar close at 144.61 with range 144.25-144.61 and low volume (3,687). The 2026-10-23 daily bar shows open 154.66, high 154.74, low 143.90, close 145.68, volume 1,344,893 (above 20-day avg of 645,633).

Intraday momentum: Minute bars from 10-23 14:30 to 10-26 13:00 show compression between 144.05 and 145.30, indicating low-volume consolidation after a volume spike down on 10-23.

Technical Analysis

SMA alignment: Price (145.68) < SMA5 (154.63) < SMA20 (168.18) < SMA50 (191.83) — full bearish stack, no bullish crossovers. RSI 19.93 indicates oversold but no reversal signal. MACD negative and histogram -2.46 confirms bearish momentum. Bollinger: price sits just above lower band (143.60), no squeeze (bands wide). 30-day range: high 223.29, low 143.90; price at 145.68 is near the very bottom (approx 1.2% above 30d low).

True Sentiment Analysis (Delta 40-60 Options)

Per True Sentiment options data 2026-10-26 13:28:

Call Volume: 150,270.00 (34.80%) Put Volume: 282,040.00 (65.20%) Total: 432,310.00

Sentiment: Bearish. Call contracts 98 vs put 155; 9 call trades vs 5 put trades. Pure directional conviction skews bearish with put dollar vol almost 2x calls. This aligns with technicals (bearish stack, oversold downtrend). No divergence between sentiment and technicals per spread engine note of "no clear direction" technically but sentiment bearish — wait for alignment advised.

Key Price Levels (Observational Only)